The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium
Information source: University Hospital, Geneva
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Neuromuscular Block
Intervention: Placebo (Drug); Lidocaine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: University Hospital, Geneva Official(s) and/or principal investigator(s): Christoph A Czarnetzki, MD, MBA, Principal Investigator, Affiliation: University Hospitals of Geneva Martin R Tramèr, MD, Dphil, Study Chair, Affiliation: University Hospitals of Geneva
Summary
Lidocaine is a local anesthetic which is widely used in daily anesthesia and surgical
practice. It has been shown that intravenous lidocaine given during an operation has
analgesic properties. Finally intravenous lidocaine is inexpensive and easy to administer
and safe if non-toxic doses are respected. It is likely that the use of lidocaine infusions
during anesthesia might increase in the coming years. Neuromuscular blockers (curare like
substances) are used in anesthesia to facilitate tracheal intubation and to achieve muscle
relaxation and immobility during surgery. Rocuronium is one of the most widely used
neuromuscular blocking agents. Local anesthetics, such as lidocaine, are known to potentiate
the effect of neuromuscular blocking agents. In the study the investigators want to evaluate
the effect of intravenous lidocaine during the operation on the time course of the
rocuronium-induced neuromuscular block. A secondary aim is to evaluate intubation conditions
(lidocaine has been shown also to improve intubation conditions) and safety.
Clinical Details
Official title: The Effect of Intravenous Lidocaine on the Time Course of Rocuronium Induced Neuromuscular Block. A Randomised, Placebo-controlled, Electrophysiological Study
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Onset and recovery of the neuromuscular block
Secondary outcome: To evaluate intubation conditions at T1, we will use the scale according to the Good Clinical Research practice (GRCP) in neuromuscular researchAny minor adverse event (no need for intervention) or major adverse event will be recorded.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult, age ≥18 to 60 years, male or female.
- American Society of Anesthesiology [ASA] status I or II.
- Patient is able to read and understand the information sheet and to sign and date the
consent form.
- Patient scheduled of elective surgery lasting longer than 120 min without need for
continuous curarisation.
- Surgery without application of local anesthetics (epidurals, wound-infiltration).
- If the patient is female and of childbearing potential, she must have a negative
pregnancy test.
Exclusion Criteria:
- A history of allergy or hypersensitivity to rocuronium or lidocaine
- Neuromuscular disease
- Preoperative medications known to influence neuromuscular function (for instance,
certain antibiotics [aminoglycosides] and anticonvulsants [phenytoine])
- Electrolyte abnormalities (for instance, hypermagnesemia)
- Hepatic or renal insufficiency
- Patients with epileptic disease
- Patients with a body mass index <19 or >28 kg m2
- Pregnant or breastfeeding women
- Expected difficult intubation or mask ventilation
- Atrioventricular heart block II or III -
Locations and Contacts
University Hospitals of Geneva, Geneva 1211, Switzerland
Additional Information
Starting date: August 2009
Last updated: July 14, 2011
|